PDGFRB and neoplasm: Sorafenib (Nexavar ®) is an orally available ATP-competitive inhibitor of Raf kinase (228) with activity against other kinases, such as BRAF, VEGFR-2 and -3, and PDGFRβ, to impede tumor growth and angiogenesis in vivo (229).